
Eli Lilly Q2 2026 Earnings: $23.0 Billion Quarter and $85–87 Billion Guide as GLP-1 Royalty Compounds
Eli Lilly Q2 2026: $23.0B revenue (+48%), $8.38 non-GAAP EPS, $85–87B guide as Mounjaro and Zepbound hit 65% of sales — tracked in a public Beancount ledger.










